SF-deferoxamine, a bone-seeking angiogenic drug, prevents bone loss in estrogen-deficient mice

Deferoxamine (DFO) possesses a good chelating capability and is therefore used for the clinical treatment of ion deposition diseases. Increasing evidence shows that DFO can inhibit the activity of proline hydroxylase (PHD) by chelating iron, resulting in hypoxia-induced factor (HIF) signaling activation and angiogenesis promotion. However, clinical evidence indicates that a high concentration of DFO could be biotoxic due to its enrichment in related organs. Thus, we established a new compound by conjugating DFO with the bone-seeking agent iminodiacetic acid (IDA); the new agent is called SF-DFO, and we verified its promotion of HIF activation and tube formation in vivo.

Source: Bone - October 30, 2018 Category: Orthopaedics Authors: Changjun Guo, Kai Yang, Yufei Yan, Dongming Yan, Yifan Cheng, Xueming Yan, Niandong Qian, Qi Zhou, Bo Chen, Min Jiang, Hanbing Zhou, Changwei Li, Fei Wang, Jin Qi, Xiangyang Xu, Lianfu Deng Tags: Full Length Article Source Type: research